by telrheum | Sep 28, 2024 | Spondyloarthritis, Acute Phase Reactants, Ankylosing Spondylitis, C-reactive Protein, JAK Inhibitor, Tofacitinib
This article presents a post hoc analysis of how baseline (BL) C-Reactive Protein (CRP) levels affect the efficacy and safety of Tofacitinib, a medication used to treat Ankylosing Spondylitis (AS). Tofacitinib is a Janus kinase inhibitor, a type of drug that helps...
by telrheum | Sep 28, 2024 | Biologic Therapy, Psoriasis, Psoriatic Arthritis
The article reports on the findings from a Phase 2 clinical trial that investigated the effectiveness of Deucravacitinib, a selective Tyrosine Kinase 2 (TYK2) inhibitor, in reducing pain in patients with active Psoriatic Arthritis (PsA). PsA is a chronic inflammatory...
by telrheum | Sep 22, 2024 | Uncategorized
The article you referenced explores the occurrence of axial spondyloarthritis (axSpA) in patients who begin experiencing chronic low back pain after the age of 45, a group that is often less studied compared to younger patients. The researchers aimed to understand the...
by telrheum | Sep 22, 2024 | Psoriasis, Pericarditis, Pleuritis, Psoriatic Arthritis, Rheumatoid Arthritis, Serositis
This study focused on comparing the frequency of serositis, which refers to inflammation of the lining around the heart (pericarditis) and lungs (pleuritis), between patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA). These conditions are types of...
by telrheum | Sep 22, 2024 | Psoriasis, Acute Phase Reactants, C-reactive Protein, Psoriatic Arthritis
The study titled “Higher Levels of High-sensitivity CRP Are Associated with Future Risk of Developing Psoriatic Arthritis Among Patients with Psoriasis” investigates whether high levels of high-sensitivity C-Reactive Protein (hs-CRP), a marker of inflammation in the...
